{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:18:28Z","timestamp":1791191908387,"version":"4.1.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:p>\n            Overactivity of the brain renin-angiotensin system has been implicated in the development and maintenance of hypertension. We reported previously that angiotensin II is converted to angiotensin III by aminopeptidase A in the mouse brain. We then used specific and selective aminopeptidase A inhibitors to show that angiotensin III is one of the main effector peptides of the brain renin-angiotensin system, exerting tonic stimulatory control over blood pressure in hypertensive rats. Aminopeptidase A, the enzyme generating brain angiotensin III, thus represents a potential candidate central nervous system target for the treatment of hypertension. Given this possible clinical use of aminopeptidase A inhibitors, it was, therefore, important to investigate their pharmacological activity after oral administration. We investigated RB150, a dimer of the selective aminopeptidase A inhibitor, EC33, generated by creating a disulfide bond. This chemical modification allows prodrug to cross the blood-brain barrier when administered by systemic route. Oral administration of RB150 in conscious DOCA-salt rats inhibited brain aminopeptidase A activity, resulting in values similar to those obtained with the brains of normotensive rats, demonstrating the central bioavailability of RB150. Oral RB150 treatment resulted in a marked dose-dependent reduction in blood pressure in DOCA-salt but not in normotensive rats, with an ED\n            <jats:sub>50<\/jats:sub>\n            in the 1-mg\/kg range, achieved in &lt;2 hours and lasting for several hours. This treatment also significantly decreased plasma arginine-vasopressin levels and increased diuresis, which may participate to the blood pressure decrease by reducing the size of fluid compartment. Thus, RB150 may be the prototype of a new class of centrally active antihypertensive agents.\n          <\/jats:p>","DOI":"10.1161\/hypertensionaha.107.098772","type":"journal-article","created":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T00:43:50Z","timestamp":1206405830000},"page":"1318-1325","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":98,"title":["Orally Active Aminopeptidase A Inhibitors Reduce Blood Pressure"],"prefix":"10.1161","volume":"51","author":[{"given":"Laurence","family":"Bodineau","sequence":"first","affiliation":[{"name":"From the Inserm (L.B., A.F., Y.M., C.F., C.L-C.), U 691, Paris, France; Colle\u0300ge de France (L.B., A.F., Y.F., C.F., C.L-C.), Paris, France; Universite\u0301 Pierre et Marie Curie-Paris VI (L.B., A.F., Y.M., C.F., C.L-C.), Paris, France; Inserm (N.I., B.R.), U640, Paris, France; Universite\u0301 Paris V (N.I., B.R.), Paris, France; and the Quantum Genomics (F.B.), Massy, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Frugie\u0300re","sequence":"additional","affiliation":[{"name":"From the Inserm (L.B., A.F., Y.M., C.F., C.L-C.), U 691, Paris, France; Colle\u0300ge de France (L.B., A.F., Y.F., C.F., C.L-C.), Paris, France; Universite\u0301 Pierre et Marie Curie-Paris VI (L.B., A.F., Y.M., C.F., C.L-C.), Paris, France; Inserm (N.I., B.R.), U640, Paris, France; Universite\u0301 Paris V (N.I., B.R.), Paris, France; and the Quantum Genomics (F.B.), Massy, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Marc","sequence":"additional","affiliation":[{"name":"From the Inserm (L.B., A.F., Y.M., C.F., C.L-C.), U 691, Paris, France; Colle\u0300ge de France (L.B., A.F., Y.F., C.F., C.L-C.), Paris, France; Universite\u0301 Pierre et Marie Curie-Paris VI (L.B., A.F., Y.M., C.F., C.L-C.), Paris, France; Inserm (N.I., B.R.), U640, Paris, France; Universite\u0301 Paris V (N.I., B.R.), Paris, France; and the Quantum Genomics (F.B.), Massy, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Inguimbert","sequence":"additional","affiliation":[{"name":"From the Inserm (L.B., A.F., Y.M., C.F., C.L-C.), U 691, Paris, France; Colle\u0300ge de France (L.B., A.F., Y.F., C.F., C.L-C.), Paris, France; Universite\u0301 Pierre et Marie Curie-Paris VI (L.B., A.F., Y.M., C.F., C.L-C.), Paris, France; Inserm (N.I., B.R.), U640, Paris, France; Universite\u0301 Paris V (N.I., B.R.), Paris, France; and the Quantum Genomics (F.B.), Massy, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ce\u0301line","family":"Fassot","sequence":"additional","affiliation":[{"name":"From the Inserm (L.B., A.F., Y.M., C.F., C.L-C.), U 691, Paris, France; Colle\u0300ge de France (L.B., A.F., Y.F., C.F., C.L-C.), Paris, France; Universite\u0301 Pierre et Marie Curie-Paris VI (L.B., A.F., Y.M., C.F., C.L-C.), Paris, France; Inserm (N.I., B.R.), U640, Paris, France; Universite\u0301 Paris V (N.I., B.R.), Paris, France; and the Quantum Genomics (F.B.), Massy, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Balavoine","sequence":"additional","affiliation":[{"name":"From the Inserm (L.B., A.F., Y.M., C.F., C.L-C.), U 691, Paris, France; Colle\u0300ge de France (L.B., A.F., Y.F., C.F., C.L-C.), Paris, France; Universite\u0301 Pierre et Marie Curie-Paris VI (L.B., A.F., Y.M., C.F., C.L-C.), Paris, France; Inserm (N.I., B.R.), U640, Paris, France; Universite\u0301 Paris V (N.I., B.R.), Paris, France; and the Quantum Genomics (F.B.), Massy, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Roques","sequence":"additional","affiliation":[{"name":"From the Inserm (L.B., A.F., Y.M., C.F., C.L-C.), U 691, Paris, France; Colle\u0300ge de France (L.B., A.F., Y.F., C.F., C.L-C.), Paris, France; Universite\u0301 Pierre et Marie Curie-Paris VI (L.B., A.F., Y.M., C.F., C.L-C.), Paris, France; Inserm (N.I., B.R.), U640, Paris, France; Universite\u0301 Paris V (N.I., B.R.), Paris, France; and the Quantum Genomics (F.B.), Massy, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Llorens-Cortes","sequence":"additional","affiliation":[{"name":"From the Inserm (L.B., A.F., Y.M., C.F., C.L-C.), U 691, Paris, France; Colle\u0300ge de France (L.B., A.F., Y.F., C.F., C.L-C.), Paris, France; Universite\u0301 Pierre et Marie Curie-Paris VI (L.B., A.F., Y.M., C.F., C.L-C.), Paris, France; Inserm (N.I., B.R.), U640, Paris, France; Universite\u0301 Paris V (N.I., B.R.), Paris, France; and the Quantum Genomics (F.B.), Massy, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","first-page":"53","volume":"62","year":"2002","unstructured":"Corvol P, Plouin PF. Angiotensin II receptor blockers: current status and future prospects. Drugs. 2002; 62: 53\u201364.","journal-title":"Drugs"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-3-234"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1994.341095026976.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1996.361097017177.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/08037059609078075"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-8-199604150-00014"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-2-1"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/07399339009515912"},{"key":"e_1_3_2_9_2","first-page":"194","volume":"12","year":"1999","unstructured":"Radevski I, Skudicky D, Candy G, Sathekge S, Strugo V, Sareli P. Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension. Am J Hypertens. 1999; 12: 194\u2013203.","journal-title":"Am J Hypertens"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6879184"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000054439"},{"key":"e_1_3_2_12_2","unstructured":"Oparil S Chen YF Berecek KH Calhoun DA Wyss JM. The role of central nervous system in hypertension. In: Laragh JH and Brenner BM eds. Hypertension: Pathology Diagnosis and Management. New York NY: Raven; 1995: 713\u2013740."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1902"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1987.253.1.1"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(95)00084-O"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.49.030187.002213"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(97)00019-2"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00035a014"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00091a016"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.21.11968"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.23.13415"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04695.x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1986.251.2.H261"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0402312101"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(01)00381-2"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00326.2002"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.107.087130"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.0000196268.08909.fb"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(96)00660-4"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi9925726"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1994.1206"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90065-Q"},{"key":"e_1_3_2_33_2","first-page":"R1265","volume":"270","year":"1996","unstructured":"Gaudet E, Blanc J, Elghozi JL. Role of angiotensin II and catecholamines in blood pressure variability responses to stress in SHR. Am J Physiol. 1996; 270: R1265\u2013R1272.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.15.9069"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M204406200"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3011.2004.00211.x"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00691850"},{"key":"e_1_3_2_38_2","first-page":"H2204","volume":"272","year":"1997","unstructured":"Lin KS, Chan JY, Chan SH. Involvement of AT2 receptors at NRVL in tonic baroreflex suppression by endogenous angiotensins. Am J Physiol. 1997; 272: H2204\u2013H2210.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.04-02-00474.1984"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.56.3.3971510"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199803300-00011"},{"key":"e_1_3_2_42_2","first-page":"1175","volume":"16","year":"1998","unstructured":"Nishimura M, Ohtsuka K, Sakamoto M, Nanbu A, Takahashi H, Yoshimura M. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats. J Hypertens. 1998; 16: 1175\u20131185.","journal-title":"J Hypertens"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198604000-00008"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-13-2-329"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(88)91401-1"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02253101"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2006.06.001"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.08.032"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.107.098772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:26:07Z","timestamp":1715592367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.107.098772"}},"subtitle":["A New Strategy for Treating Hypertension"],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.107.098772"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.107.098772","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"2007-07-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-02-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}